Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors

Xiaocong Yu, Tshidi Tsibane, Patricia A. McGraw, Frances S. House, Christopher J. Keefer, Mark D. Hicar, Terrence M. Tumpey, Claudia Pappas, Lucy A. Perrone, Osvaldo Martinez, James Stevens, Ian A. Wilson, Patricia V. Aguilar, Eric L. Altschuler (), Christopher F. Basler () and James E. Crowe ()
Additional contact information
Xiaocong Yu: Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
Tshidi Tsibane: Mount Sinai School of Medicine
Patricia A. McGraw: Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
Frances S. House: Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
Christopher J. Keefer: Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
Mark D. Hicar: Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
Terrence M. Tumpey: Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
Claudia Pappas: Mount Sinai School of Medicine
Lucy A. Perrone: Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
Osvaldo Martinez: Mount Sinai School of Medicine
James Stevens: Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
Ian A. Wilson: The Scripps Research Institute, La Jolla, California 92037, USA
Patricia V. Aguilar: Mount Sinai School of Medicine
Eric L. Altschuler: University of Medicine & Dentistry of New Jersey, Newark, New Jersey 07103, USA
Christopher F. Basler: Mount Sinai School of Medicine
James E. Crowe: Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA

Nature, 2008, vol. 455, issue 7212, 532-536

Abstract: A lifetime fighting flu The isolation of neutralizing antibodies to proteins from the 1918 H1N1 influenza virus from the blood of pandemic survivors sets a new yardstick for the persistence of an immune response. The blood samples were collected from 32 survivors aged between 91 and 101 years. They were 2 to 12 years old in 1918. All were seroreactive to the recently re-created 1918 virus, and it was possible to isolate memory B cells from some of the samples and grow them in culture. The B cells produced antibodies to a 1918 virus protein that protected mice from lethal infection by the 1918 virus. This suggests that they could serve as potential therapeutics of an emergent 1918-like virus.

Date: 2008
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/nature07231 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:455:y:2008:i:7212:d:10.1038_nature07231

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature07231

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().